Generation of the MYCN/NCYM mouse model and the drug discovery for human neuroblastoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24249061
• Research Category: Grant-in-Aid for Scientific Research (A)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Pediatrics
• Research Institution: Kyushu University (2014); Chiba Cancer Center (Research Institute) (2012-2013)
• Principal Investigator: NAKAGAWARA Akira 九州大学, 医学(系)研究科(研究院), 研究員 (50117181)
• Co-Investigator(Kenkyū-buntansha): OOHIRA Miki 千葉県がんセンター(研究所), がんゲノム研究室, 室長 (20311384)
• Co-Investigator(Renkei-kenkyūsha): TAKATORI Athushi 千葉県がんセンター(研究所), がん遺伝創薬研究室, 研究員 (40455390) ; NAKAMURA Youko 千葉県がんセンター(研究所), がん予防センター, 主席研究員 (60260254) ; SUENAGA Yusuke 千葉県がんセンター(研究所), 臨床ゲノム研究室, 研究員 (80581793)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 創薬 / 神経芽腫 / in silico screening / TrkB / ALK / ShcC / NCYM / MYCN

Outline of Final Research Achievements

In this study, we developed new drugs against high-risk neuroblastoma. By targeting TrkB and ALK/ShcC proteins, we successfully identified more than several small chemical compounds that efficiently kill neuroblastoma cells. In addition, the candidate therapeutic monoclonal antibodies targeting NLRR1 were also generated. Furthermore, the NCYM/MYCN double transgenic mice we generated revealed to be suitable for screening new candidate drugs against high-risk human neuroblastoma.

Free Research Field

小児外科学分野